BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic antibody therapeutics, today announced the appointment of Scott Smith.

Mr. Smith, an experienced biotechnology and pharmaceutical executive, joins the Company from Celgene Corporation, where he was President and Chief Operating Officer.

“Scott’s experience and proven capabilities in building and leading organizations for the development and commercialization of innovative products makes him ideally suited to help lead the expansion of BioAtla’s operations, including business development and partnering activities, new product development and execution of our strategies to advance our CAB platform opportunities worldwide. I look forward to working with Scott to build on and accelerate BioAtla’s progress,” said Jay M. Short.

Mr. Smith joins BioAtla with 30 years of biotechnology and pharmaceutical industry experience.

In his ten years at Celgene from 2008-2018 his leadership role expanded from Vice President of Global Marketing for Inflammation & Immunology, to Global Head of that division, to President of the Inflammation & Immunology Franchise to his appointment in 2017 as Celgene’s President and Chief Operating Officer.

With a particular emphasis and interest in immunology, Mr. Smith drove the growth of Celgene’s Inflammation and Immunology division from 13 to more than 1,300 people worldwide and oversaw the clinical development, global registration and commercial success of the blockbuster drug Otezla.

BioAtla develops novel monoclonal antibody and other protein therapeutic product candidates designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies.